Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?
Basi
Seema
S
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Fesler
Pierre
P
Mimran
Albert
A
Lewis
Julia B
JB
D000419:Albuminuria / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000652:urine; D001794:Blood Pressure / Q000502:physiology; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000652:urine; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis*; D003925:Diabetic Angiopathies / Q000503:physiopathology / Q000652:urine*; D003928:Diabetic Nephropathies / Q000503:physiopathology / Q000652:urine; D017328:Fosinopril / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology / Q000652:urine*; D015995:Prevalence; D011507:Proteinuria / Q000209:etiology
D000959:Antihypertensive Agents; D015415:Biomarkers; D017328:Fosinopril